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Immunodeficiencyconsidered when the body mass index (BMI) is o18.5 kg/m2. If normal food intake
including nutritional counselling and optimal use of ONS cannot achieve an adequate
nutrient intake, TF with standard formulae is indicated. Due to conflicting results
from studies investigating the impact of immune-modulating formulae, these are not
generally recommended. The results obtained in HIV patients may be extrapolated
to other chronic infectious diseases, in the absence of available data.
The full version of this article is available at www.espen.org.
& 2006 European Society for Clinical Nutrition and Metabolism. All rights reserved.Summary of statements: HIVSubject Recommendations Grade 71 NumberIndications Nutritional therapy is indicated when significant
weight loss (45% in 3 months) or a significant loss
of body cell mass (BCM) (45% in 3 months) has
occurred.B 2.1Nutritional therapy should be considered when the
BMI is o18.5 kg/m2.C 2.1Diarrhoea and/or malabsorption are no
contraindication to EN, because:
 Diarrhoea does not prevent a positive effect of
oral nutritional supplements or TF on nutritional
status.A 2.4 Enteral and parenteral nutrition (PN) have
similar effects in such patients.A 2.4 Enteral nutrition has a positive impact on stool
frequency and consistency.A 2.4Application The combination of normal food and enteral
nutrition is appropriate in many cases and should
be attempted.C 3.6If oral intake is possible, nutritional intervention
should be implemented according the following
scheme.C 2.2 nutritional counselling
 oral nutritional supplements
 tube feeding (TF)
 PNEach of the steps should be tried for 4–8 weeks
before the next step is initiated.Nutritional counselling with oral nutritional
supplements, or counselling alone, are equally
effective at the beginning of nutritional support
and/or for preserving nutritional status.B 2.2In settings where qualified nutritional counselling
cannot be provided, oral nutritional supplements
may be indicated in addition to normal food but
this should be limited in time.C 2.2Protein intake should achieve 1.2 g/kg bw/day in
stable phases of the disease while it may be
increased to 1.5 g/kg bw/day during acute illness.B 3.2Energy requirements are no different from other
patient groups.
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supplements are not effective: If normal food
intake and optimal use of oral nutritional
supplements cannot achieve sufficient energy
supply, TF is indicated.C 2.3Drug treatment and enteral nutrition complement
each other.C 2.5Route Use antibiotic prophylaxis during implantation of
percutaneous endoscopic gastrostomy (PEG).A 3.4Type of formula Use standard formulae. B 3.1
In patients with diarrhoea and severe
undernutrition MCT containing formulae are
advantageous.A 3.1Immune modulating formulae are not
recommended.3.1Grade: Grade of recommendation; Number: refers to statement number within the text.Summary of statements: Other Chronic Infectious DiseasesSubject Recommendations Grade 71 NumberIndication Nutritional support should be given to patients
with undernutrition resulting from infectious
diseases, based on generic indication and
procedures.C 4Type of formula Prefer oral nutritional supplements. B 4Outcome Nutritional support has been shown to increase
weight gain during treatment of pulmonary
tuberculosis.4
Grade: Grade of recommendation; Number: refers to statement number within the text.IntroductionNutritional intervention in chronic infections has
been studied mainly in patients infected with the
human immunodeficiency virus (HIV). There are
few, if any data from other chronic infections, such
as tuberculosis. These guidelines will therefore
concentrate mainly on HIV infection.
1. Interrelations of disease, nutritional
status and prognosis
1.1. What is the impact of HIV infection on
nutritional status and metabolism?
Weight loss may occur at all stages of HIV
disease. Seroconversion often manifests as
severe systemic disease with weight loss fol-
lowed by spontaneous recovery. Weight loss
occurs in about one-third of patients in theasymptomatic latent phase and is invariable in
the symptomatic and end stage phases of the
disease.
Comment: The HIV Wasting Syndrome is defined
as weight loss (410%) with fever and/or diarrhoea
of unknown origin,1 although some wasting may
occur in the absence of these symptoms. Rapid
wasting is usually a manifestation of opportunistic
infection or malignancy in late AIDS with advanced
immunodeficiency.2–4 Changes in weight more
subtle than the 10% weight loss specified in the
centre for disease classification and prevention
(CDC) definition1 may also have an adverse impact
on health.
The introduction of highly active antiretroviral
treatment (HAART) in 1996 has decreased the
incidence of wasting,12 and it is now seen mostly
in patients who have never been treated or where
treatment has failed due to drug intolerance or
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guished from lipodystrophy, which is a frequent
complication of antiretroviral treatment, and is
manifest as fat redistribution with loss of subcuta-
neous fat, increase in intra-abdominal fat, buffalo
hump or breast hypertrophy.5 Body weight may
increase or decrease depending on the relation
between subcutaneous lipoatrophy and intra-ab-
dominal lipohypertrophy. HAART-associated lipody-
strophy normalises the resting energy expenditure
(REE), but has only minor effects on lipolysis as a
result of concomitant sympathetic stimulation of
adipose tissue.6 The HAART-induced changes in
metabolism seem to be permanent, as discontinua-
tion of HAART has no influence on the degree of
lipodystrophy.7
Medical treatment of lipodystrophy seems not to
be effective8 but avoiding antiretroviral drugs with
strong metabolic adverse effects may prevent or
partially reverse lipodystrophy9–11 (Ib).
In case of weight loss despite sufficient HAART
special consideration has to be given to12: depression,
 anorexia,
 self-neglect (e.g. drug abusers),
 dry mouth, lack of saliva caused by medication
(e.g. antiviral therapy).1.2. Which specific diagnostic procedures are
recommended in HIV-infected patients with
weight loss?
In addition to standard nutritional assessment
the following points should be considered: Search for an opportunistic infection or other
complications of disease or therapy.
 Determine testosterone concentration (B).13 Determine LH/FSH, thyroid function (C).
 Look for signs of lipodystrophy (loss of
subcutaneous fat, triceps skinfold thickness,
waist/hip ratio).
 Exclude treatment-induced diabetes melli-
tus.14 If nausea/vomiting: is this an adverse drug
reaction?
 Exclude malassimilation/malabsorption.
 Is there a lack of saliva production?
 If abdominal pain or dysphagia: suspect
candida oesophagitis, and perform upper GI
endoscopy or therapeutic trial with flucona-
zole.
 Start nutritional support while awaiting re-
sults of the diagnostic tests.Comment: Distinguish between predominant
muscle mass depletion (wasting) and peripheral
fat loss (lipoatrophy) by changes in body shape and
muscular function. Wasting and lipoatrophy may be
combined in patients failing on long-term antire-
troviral treatment.
1.3. Does nutritional status influence prognosis
(survival)?
The prognosis of advanced HIV infection is
influenced by undernutrition. Decreased nutri-
tional status in HIV-infected patients is
associated with an increased mortality, inde-
pendently of immunodeficiency and viral load.
Comment: Undernutrition correlates with increased
mortality 4,15–17 (IIb) despite recent decreases in the
prevalence of undernutrition and wasting in western
countries (as opposed to developing countries) due
to the use of HAART.18,19 It remains to be seen
whether HAART will change the way that under-
nutrition presents in this condition.
Nutritional status in HIV is best reflected by
muscle mass representing the structural protein
pool. Untreated HIV infection is characterised by
early loss of structural protein, loss of lean body
mass (LBM), and more precisely by loss of BCM16
which cannot be measured directly in routine
clinical care. Indirect measures of BCM are based
on regression equations that are insufficiently well
validated.20,21 The phase angle from bioelectrical
impedance analysis (BIA) is a measure of capacitive
resistivity of cell walls and of the ratio between
extra- and intracellular water, which together with
the estimate of BCM derived from it are indepen-
dent prognostic markers in HIV infection 15,22 (IIb),
16 (III).
Loss of muscle and visceral mass may be masked
by an increase in extracellular fluid and/or fat
mass, which may explain why body weight, body
mass index and history of weight loss have not been
shown to predict prognosis reliably.
Decreased serum levels of albumin and transfer-
rin are also adverse prognostic markers 16 (III),
although this may relate to their value as surrogate
markers of an acute phase response.
2. Aims of nutritional support
Nutritional intervention aims to: improve nutritional status,
 decrease functional impairment from undernu-
trition (muscular fatigue, bedridden state, work
incapacity),
 improve tolerance to antiretroviral treatment,
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(nausea, diarrhoea, bloating),
 improve quality of life.
2.1. What are the indications for nutritional
counselling or EN in HIV?
Nutritional therapy is indicated when significant
weight loss (45% in 3 months) or a significant
loss of BCM (45% in 3 months) has occurred (B).
In addition, nutritional therapy should be con-
sidered when the BMI is o18.5 kg/m2 (C).
Comment: Institution of nutritional support should
be preceded by a search for a potential reason for
undernutrition. General rules about the indications
for nutritional support are valid in HIV infection.
There is a lack of controlled intervention trials
supporting the use of TF over normal food. Some
open randomised trials compare different types of
nutritional support. Choice of the mode of nutri-
tional support is therefore based on expert opinion
only.
All randomised controlled trials of EN in HIV-
infected patients have been conducted in popula-
tions with normal or only mildly impaired nutri-
tional status.23–28 Positive outcome of nutritional
intervention in patients with advanced AIDS wast-
ing has been described in several non-controlled
observation trials 27,29–34 (III). PEG is feasible in HIV
patients and should be considered as an option
5,3,30–32,34,35 (III). A small controlled trial in two
groups of eight moderately malnourished HIV-
infected patients demonstrated a decrease in
protein oxidation in patients receiving ONS, com-
pared to patients receiving nutritional counselling
alone 25 (IIb). These limited data are compatible
with a decrease in protein catabolism as shown for
PN in advanced AIDS 36 (IIb).
Only one small multicentre prospective con-
trolled trial of total parenteral nutrition (TPN)
versus nutritional counselling was conducted in
severely immunocompromised and malnourished
patients (N ¼ 31) with severe digestive disease,
but free of opportunistic infections. The results
were an increase of 7 kg in LBM in 2 months of
treatment in the treated group with an increase in
survival and quality of life, while at the same time
the control group continued to lose weight 37,38 (Ib)
TPN should be used only in patients who are not
able to feed enterally. Ethical considerations have
rightly prevented the conduct of large powerful
controlled studies of nutritional intervention which
include an untreated control group in severely
malnourished patients with AIDS, as most experts
agreed on the need to give nutritional support in
the presence of significant malnutrition. This hasled to a lack of unequivocal evidence for its
efficacy.
2.2. How should nutritional support be initiated
in HIV-infected patients without dysphagia?
If oral intake is possible, nutritional interven-
tion should be implemented according the fol-
lowing scheme (C). Each of the steps should be




 PN.Nutritional counselling with ONS, or counselling
alone, are equally efficient at the beginning of
nutritional support and/or for preserving nutri-
tional status (B). In settings where qualified
nutritional counselling cannot be provided, ONS
may be indicated in addition to normal food but
this should be limited in time (C).
Comment: In a Chilean crossover study, supple-
mentation with a whole protein formulae was more
effective in malnourished, symptomatic HIV-in-
fected patients than normal food alone over a 45-
day period with regard to weight gain and LBM 39
(IIa). Nutritional counselling with and without ONS
were compared in two controlled trials the with
following results 40,41 (Ib). Body weight, LBM and
BCM were increased in both intervention groups to
the same extent. There was marginally greater
energy intake in patients receiving ONS. A recent
Cochrane review highlights the role of nutritional
counselling and ONS in the management of illness-
related undernutrition including a small population
of HIV positive and mainly HIV negative patients.
These results suggest ONS may be more effective
than nutritional counselling, or provide an addi-
tional benefit in enhancing short-term weight
gain.42,43
In addition, in asymptomatic HIV-infected
patients no difference in nutritional or immunolo-
gical parameters was observed between a control
group with nutritional counselling alone (n ¼ 19)
compared to a group with additional standard ONS
(n ¼ 26), and a group with an immune-modulating
ONS (n ¼ 31). Study participants were followed for
1 year. The immune-modulating formula was
enhanced with arginine, glutamine, omega-3 fatty
acids, and antioxidative vitamins 44 (Ib).
ONS have not been formally tested in the absence
of nutritional counselling, since, if nutritional
counselling is available, it would be considered
ARTICLE IN PRESS
J. Ockenga et al.324unethical. If such counselling is unavailable it is
appropriate to give ONS without it.
ONS may increase the total energy intake for two
to six weeks, however, later on increases are
minimal 26,27,29–31,33,34 (III), 40 (Ib). Patients should
be advised to use ONS between meals, to avoid
interfering with oral intake at meal times. No data
are available regarding the optimal duration of the
nutritional counselling or ONS before escalating to
more invasive nutritional strategies. This has to be
decided individually according to the clinical
situation.
2.3. How should nutritional support be initiated
in HIV-infected patients with dysphagia, or if ONS
are not effective?
If normal food intake and optimal use of ONS
cannot achieve sufficient energy supply, TF is
indicated (C).
Comment: Comparison of actual oral intake with
estimated needs should be part of the evaluation.
When weight gain is not achieved despite meeting
nutritional targets there should be a re-evaluation
of the adequacy of those targets, before resorting
to TF. Clinical studies of TF have been conducted in
patients where oral interventions (i.e., nutritional
counselling and ONS) had failed or in those unable
to swallow food.29–32,34 All studies have documen-
ted some weight gain, but those that have
measured body composition have shown gain in
fat rather than muscle mass. Participants in such
studies were mostly bedridden and inactive, which
may have contributed to the failure to regain lean
mass since, in the absence of physical activity,
nutritional support alone is unlikely to restore
muscle. Similarly, during episodes of rapid weight
loss, physical activity is reduced in HIV-infected
patients, as demonstrated by the doubly labelled
water method.45
No controlled studies comparing normal food and
EN in patients with AIDS wasting have been
published.
2.4. Is EN indicated in patients with diarrhoea
and/or malabsorption?
Yes, EN is indicated in patients with diarrhoea
for the following reasons: Diarrhoea does not prevent a positive effect
of ONS or TF on nutritional status (A).
 Enteral and PN have similar effects in such
patients (A).
 EN has a positive impact on stool frequency
and consistency (A).Comment: Abnormalities of intestinal absorption
have been demonstrated in patients with HIV
wasting and in patients without wasting. The
functional significance of such abnormalities varies
between individuals and the impact of such findings
on the outcome of nutritional intervention is
unclear. Functional tests of absorption should be
initiated individually.
In patients with diarrhoea and severe malabsorp-
tion, a controlled trial over three months of
peptide based ONS versus PN showed similar
efficacy, but PN was more expensive46 (Ib). Patients
on PN achieved higher energy intake and gained
more weight but this was almost entirely due to
gain in fat mass. The effect on LBM is impaired by
opportunistic infection17 and enhanced by physical
exercise. Those receiving EN had better quality of
life and greater physical activity.
2.5. What is the role of anabolic drug treatment
in HIV associated undernutrition?
Drug treatment and EN may complement each
other (C).
HIV positive patients with testosterone defi-
ciency should receive testosterone substitution
to restore muscle mass (A). Moderate gain in
body weight and fat free mass can be achieved
by recombinant human growth hormone (rhGH)
at high cost (A).
Comment: Randomised placebo controlled trials in
patients with wasting and low testosterone con-
centration showed positive effects of testosterone
substitution on fat free mass, muscle mass and
quality of life 24,48 (Ib).
Likewise, women with HIV wasting have low
testosterone 49 (IIb). A pilot intervention trial in
hypogonadal women showed some positive effects
of testosterone substitution of 150 mg/day like
increase in muscle mass strength 50 (IV), but no
significant weight gain or muscle mass gain could
be observed 51 (IIA). It is currently not licensed for
use in HIV wasting in Europe.
In a recent meta-analysis eight trials of testos-
terone therapy met the inclusion criteria and 417
randomised patients were included 52 (Ia). Only six
trials used LBM, fat free mass, or BCM as outcome
measures. All eight trials included total body
weight as an outcome measure, the meta-analysis
of which showed a difference of 1.04 kg
(0.01–12.10) between testosterone group and
placebo group by random effect and 0.63 kg
(0.01–1.28) for fixed effect models. Overall, the
incidence of adverse effects was similar in both
groups. Testosterone therapy was shown in this
review to increase LBM more than placebo. These
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and heterogeneity of the population, which poten-
tially introduced bias into the methods and results.
Testosterone therapy may be considered in patients
with HIV wasting syndrome to reverse muscle loss,
but there is a concern about the adverse metabolic
effects of long-term testosterone administration
and long-term follow-up for these patients is
needed.
An rhGH and anabolic steroids may increase fat
free mass and muscle mass 53,54 (Ib), 55 (IIb). In
patients on HAART who had lost 410% of weight,
rhGH in two different doses led to 1.5 and 2.2 kg
weight gain compared to placebo. This consisted
mainly of increased LBM whilst body fat mass
was lost. Health-related quality-of-life indices
improved with rhGH 48 (Ia). This confirms the
results of earlier trials conducted before the
advent of HAART.53 As rhGH is much more expensive
than HAART, other treatment options should be
exhausted before using rhGH, particularly in health
care settings where drug budgets are limited (III).
In a placebo controlled trial treatment with the
anabolic steroid oxymetholone (100mg/day) re-
sulted in an increase in body weight, muscle mass,
and functional parameters, but the effect was
limited by a significant dose-dependent liver
toxicity in 30% of the patients 54 (Ib). Appetite
may be increased by treatment with high doses of
megestrol acetate and this is associated with
weight gain, although, in men, the weight gained
consist almost entirely of fat mass.56,57 Whilst
cannabinoids may improve perceived appetite,
they do not impact weight to the same extent58
(Ib). The use of these drugs is limited by high cost
and adverse reactions.
Thalidomide may reduce proinflammatory, cata-
bolic cytokines like TNF-a. In a double blind,
placebo-controlled trial in undernourished HIV-
infected patients, thalidomide was associated with
a significant mean weight gain after 8 weeks of
study treatment (2.2 kg (100mg talidomide/day)
versus 1.5 kg (200mg thalidomide/day) versus
0.9 kg (placebo) but changes in fat free mass were
no different to placebo 59 (Ib). In the experimental
group a modest increase in HIV load was recog-
nised, consistent with the results of previous
studies of Thalidomide in HIV infection, although
this occurred very rapidly and may, at least in part,
have been related to fluid accumulation. In addi-
tion, approximately 30% of the patients discontin-
ued treatment due to adverse reactions.
Note that almost all controlled studies were
conducted in patients before the introduction
of HAART. Therefore, the efficacy of anabolic
drug treatment in populations with access tomodern drugs needs to be reassessed in future
studies.3. Practical application of EN
3.1. What type of enteral formulae should be
used?
Generally, no advantage for any specific formula
has been shown. Standard formulae should
therefore be used (B), although in patients with
diarrhea and severe undernutrition, MCT con-
taining formulae are advantageous (A).
Conflicting results have been obtained from
studies investigating the impact of immune-
modulating formulae. They are not therefore
recommended.
Comment: Oral nutrition enriched with arginine
(14 g/day), glutamine (14 g/day) and b-hydroxy-
b-methylbutyrate (3 g/day) led to more gain in
muscle mass and was associated with decreased
HIV viral load in a placebo-controlled randomised
trial 60 (Ib). Both treated and control groups gained
weight. The additional caloric intake was 200 kcal/
day in both groups but because the placebo was not
isonitrogenous, protein intake was only increased
in the treated group.
Another randomised, placebo-controlled trial
investigated the effect of ONS (660 kcal/day), with
or without added arginine (7.4 g/day) and o-3 fatty
acids (1.7 g/day).26 No advantage of the arginine/
o-3 fatty acid supplement was demonstrated; both
groups achieving weight gain (Ib). The same type of
supplement was studied in a cross-over blinded
trial and achieved higher weight gain than placebo
27 (IIa).
In asymptomatic HIV patients, ONS enriched with
oligopeptides and other proteins (19%) and carbo-
hydrates (65%) but depleted of fat (16%) led to
greater weight gain and were associated with
reduced hospitalisation.24 However, the results
of this study are doubtful because the two
interventions were not comparable in energy and
nutrient content. Again, such data were obtained
before the introduction of HAARTand are therefore
not easily applicable to current patient popula-
tions.
An ONS enhanced with arginine, glutamine,
omega-3 fatty acids, and antioxidative vitamins
was investigated in asymptomatic HIV-infected
patients on HAART. The findings of this study
suggest that one year of supplementation with
standard and immune-modulating ONS have neither
therapeutic nor differential effects 44 (Ib).
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rhoea, two types of nutritionally complete ONS
containing either LCTor MCTas fat were associated
with an improvement in stool frequency and
consistency, whereas the MCT based supplement
was superior to the LCT based supplement 47 (Ib).
3.2. What is an adequate energy and protein
intake in HIV?
The target for protein intake should be 1.2 g/kg
bw/day in stable phases of the disease while it
may be increased to 1.5 g/kg bw/day during
acute illness (B). Energy requirements are no
different from other patient groups.
Comment: There is no evidence that the energy
requirement of HIV sufferers is any different from
other patients groups. Studies of total energy
expenditure have not demonstrated hypermetabo-
lism.45 Such studies, however, were not designed to
evaluate the requirements for energy intake,
although they did demonstrate the importance of
adequate energy intake. According to a World
Health Organization (WHO) working group an intake
above 10% of expected energy requirement should
be recommended during weight recovery.
During the recovery phase after opportunistic
infections, hypermetabolism is common and energy
requirements may be increased by 20–30% in order
to provide substrates for weight regain. Similarly,
the anabolic phase after initiation of HAART is
likely to increase energy requirements.
Studies of nitrogen balance using stable isotopes
have demonstrated positive nitrogen balance in
symptomatic HIV patients with a protein intake
between 1.2 and 1.8 g/day 36 (IIa). No controlled
trials have addressed this question. Likewise, dose
response has not been studied systematically.
3.3. Have specific complications of enteral
nutrition been observed in HIV positive patients?
Local infections, with or without limited perito-
nitis, have been observed in HIV patients with
PEG feeding more often than in other popula-
tions.
Comment: Two investigations have demonstrated
higher rates of local infection at the exit site of
PEG in HIV positive patients, mostly in those with
advanced immunodeficiency. However, severe com-
plications were not found more frequently than in
control populations 35,61 (IIb). Antibiotic prophy-
laxis was given to all patients in these studies.
3.4. Is antibiotic prophylaxis recommended dur-
ing implantation of percutaneous endoscopic
gastrostomy (PEG) in HIV-infected patients?As in all patients, antibiotic prophylaxis is
recommended (A).
Comment: Sepsis or other severe infectious com-
plications are rare after implantation of PEG. A
single dose of a broad-spectrum antibiotic covering
anaerobes reduced the rate of peristomal infection
in HIV negative populations 62,63 (Ib). In the
absence of specific controlled trials in HIV-infected
patients, these data can be applied to HIV positive
patients where such complications are expected
more frequently.
All published studies on PEG feeding in HIV-
infected patients have used antibiotic prophylaxis
30,35 (IV).
3.5. When is EN contraindicated in HIV-infected
patients?
General contraindications for EN apply to HIV-
infected patients, no additional considerations
must be taken into account.
3.6. Should EN be combined with normal food
intake?
The combination of normal food and EN is
appropriate in many cases and should be
attempted (C).
Comment: ONS may increase total energy intake by
about 20% for limited periods. They should be
prescribed, where available, as part of a structured
nutritional counselling process 25,33,40,41 (IIb–III).
The effect should be evaluated after 2–3 months.
Long-term nasoduodenal, nasogastric and percuta-
neous TF are only rarely indicated in patients who
can be maintained on HAART. If oral intake during
the day is insufficient due to causes that cannot be
influenced (e.g. lack of saliva, neurological causes)
then nocturnal TF may be used to increase nutrient
intake. Particularly at home this is a very comfor-
table way of combining oral (social!) feeding with
an optimised intake.4. Can findings from HIV wasting be
extrapolated to or from findings in other
infectious diseases?
Nutritional support has been shown to increase
weight gain during treatment of pulmonary
tuberculosis. Nutritional intervention has not
been studied sufficiently in most other infec-
tious diseases. However, nutritional support
should be given to patients with undernutrition
resulting from such diseases, based on generic
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support, ONS are preferred (B).
Comment: Pulmonary tuberculosis is the classical
wasting disease. Weight loss is almost invariably
seen at diagnosis in resource poor settings.64 In
industrialised countries, between 30%65 and 80% of
patients are undernourished at diagnosis of pul-
monary tuberculosis.66 Moderate to severe under-
nutrition is associated with an increased risk of
death within the first four weeks of antituberculous
treatment.67 Antimicrobial treatment allows
weight gain in most cases but this may be
delayed.68 Furthermore, weight gain without nutri-
tional intervention consists almost entirely of fat
mass 69 (IIb).
ONS (600–900 kcal/day) were superior to nutri-
tional counselling alone with regard to gains in
weight, fat free mass and muscle strength in
patients with pulmonary tuberculosis who had lost
weight 70 (Ib).
Many centres provide nutritional support to
patients treated for multi-drug resistant tubercu-
losis. This is clinically appropriate as it may reduce
the impact of longstanding disease and toxic
second-line treatment, as well as improving ad-
herence to treatment.
There are virtually no data on the impact of
nutritional support in other chronic infections
associated with wasting, such as visceral leishma-
niasis or brucellosis.2
Acute infections only provide an indication for EN
if recovery from a catabolic state cannot be
expected within days, e.g. in the absence of
effective antimicrobial treatment, if normal food
intake cannot be established over 7 days or longer,
or if the patient is already undernourished because
of other underlying disease.References
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